Presentation is loading. Please wait.

Presentation is loading. Please wait.

FIGURE 1 Patient enrolment flowchart. SBS, short bowel syndrome.

Published byFanny Tedja Modified over 5 years ago

Similar presentations

Presentation on theme: "FIGURE 1 Patient enrolment flowchart. SBS, short bowel syndrome."— Presentation transcript:

1 FIGURE 1 Patient enrolment flowchart. SBS, short bowel syndrome.
Unless provided in the caption above, the following copyright applies to the content of this slide: Copyright © American Society for Nutrition 2019.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Am J Clin Nutr, Volume 109, Issue 4, 29 March 2019, Pages 1112–1118, The content of this slide may be subject to copyright: please see the slide notes for details.

2 FIGURE 2 Cause of small bowel resection
FIGURE 2 Cause of small bowel resection. NEC, necrotizing enterocolitis; SBS, short bowel syndrome. FIGURE 2 Cause of small bowel resection. NEC, necrotizing enterocolitis; SBS, short bowel syndrome. Unless provided in the caption above, the following copyright applies to the content of this slide: Copyright © American Society for Nutrition 2019.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Am J Clin Nutr, Volume 109, Issue 4, 29 March 2019, Pages 1112–1118, The content of this slide may be subject to copyright: please see the slide notes for details.

3 FIGURE 3 Comparison by ANOVA between type of SBS and small bowel length (A), energy absorption rate (B), fecal sodium ... FIGURE 3 Comparison by ANOVA between type of SBS and small bowel length (A), energy absorption rate (B), fecal sodium output (C), and plasma citrulline concentrations (D) expressed in box plots. **P < 0.05. SBS, short bowel syndrome. Unless provided in the caption above, the following copyright applies to the content of this slide: Copyright © American Society for Nutrition 2019.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Am J Clin Nutr, Volume 109, Issue 4, 29 March 2019, Pages 1112–1118, The content of this slide may be subject to copyright: please see the slide notes for details.

4 FIGURE 4 Predicted average percentage absorption per SBS type, adjusted for relative bowel length, age, fecal sodium ... FIGURE 4 Predicted average percentage absorption per SBS type, adjusted for relative bowel length, age, fecal sodium output, and fecal potassium output, n = 32. SBS, short bowel syndrome. Unless provided in the caption above, the following copyright applies to the content of this slide: Copyright © American Society for Nutrition 2019.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Am J Clin Nutr, Volume 109, Issue 4, 29 March 2019, Pages 1112–1118, The content of this slide may be subject to copyright: please see the slide notes for details.

5 FIGURE 5 Small bowel length–citrulline relation
FIGURE 5 Small bowel length–citrulline relation. Solid line: regression of small bowel length on citrulline not ... FIGURE 5 Small bowel length–citrulline relation. Solid line: regression of small bowel length on citrulline not accounting for SBS type, n = 32. SBS, short bowel syndrome. Unless provided in the caption above, the following copyright applies to the content of this slide: Copyright © American Society for Nutrition 2019.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Am J Clin Nutr, Volume 109, Issue 4, 29 March 2019, Pages 1112–1118, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "FIGURE 1 Patient enrolment flowchart. SBS, short bowel syndrome."

Similar presentations

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
FIGURE 1 Distribution of total body iron (calculated from serum ferritin and soluble transferrin receptor ... FIGURE 1 Distribution of total body iron.

FIGURE 1 Distribution of total body iron (calculated from serum ferritin and soluble transferrin receptor ... FIGURE 1 Distribution of total body iron.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Schematic representation of the experimental design.

Figure 1 Schematic representation of the experimental design.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
FIGURE 1 Percentage of patients with sarcopenia or low SMD across the spectrum of total adiposity (N = 3262). SMD, ... FIGURE 1 Percentage of patients.

FIGURE 1 Percentage of patients with sarcopenia or low SMD across the spectrum of total adiposity (N = 3262). SMD, ... FIGURE 1 Percentage of patients.
FIGURE 1 PRISMA flow diagram of studies in systematic review

FIGURE 1 PRISMA flow diagram of studies in systematic review
Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.

Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.
Figure 1 Phases of the research. Author’s own work.

Figure 1 Phases of the research. Author’s own work.
FIGURE 1 Flowchart of the study population.

FIGURE 1 Flowchart of the study population.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.
RCTs: randomized controlled ...

RCTs: randomized controlled ...

Similar presentations

Ads by Google